Yvonne Saenger, MD
- ASSISTANT CLINICAL PROFESSOR | Medicine, Hematology and Medical Oncology
Dr. Yvonne Saenger completed her undergraduate training at Harvard University, attended medical school and residency at Columbia University and completed a fellowship in oncology with a focus on melanoma at Memorial Sloan Kettering and a fellowhip in immunotherapy at Johns Hopkins Medical Center. Her clinical focus is on melanoma and immunotherapy and her research focus is on immunotherapy and immune biomarkers. Dr. Saenger is the principal investigator of multiple immunotherapy studies at Mount Sinai. She is the recipient of a Dermatology Foundation Career Development Award and has developed a novel immune biomarker to predict survival in patients with resected stage II and stage III melanoma. In her laboratory, researching combination of oncolytic virotherapy with other therapeutic modalities. Dr. Saenger recently presented her biomarker work at the Society for the Immunotherapy of Cancer.
- A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Previously Untreated, Unresectable, Stage IIIb-IV Melanoma
The purpose of this study is to find out more about talimogene laherparepvec (formerly known as OncoVEXGM-CSF), in people with advanced melanoma when given in combination with another drug called ipilimumab. Melanoma is a type of skin cancer. Advanced melanoma means the ...
- A Multi-center, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence
The purpose of this study is to confirm the safety of the investigational vaccine POL-103A and test if its administration on a regular schedule can increase the immune system activity, which is thought to delay the melanoma from coming back.